The BRIGhTMIND trial, led by Neuromod+ member Richard Morriss at Nottingham University, has reported that the use of TMS in conjunction with MRI scans could ease symptoms of depression for up to six months. See details of the study “Connectivity-guided intermittent theta burst versus repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled trial” reported in Nature Medicine, and reports in the media, including by UKRI and The Independent.
Co-creation for next-generation neuromodulation therapeutics
Co-creation for next-generation neuromodulation therapeutics
Neuromod+ introduces a promising MRI technique that could potentially offer new hope for patients battling severe depression. This innovation signifies a significant advancement in mental health diagnostics and treatment strategies. Thank you for sharing this promising development in the field of neuroimaging.